Susanne Schneider, MD, PhD, University Hospital Munich, Munich, Germany, comments on conducing long-term surveillance in patients with Parkinson’s disease who have contracted COVID-19. Such data are currently available and analysis of these patients over a longer period of time will enable healthcare systems to prepare for similar events in the future. Genetic risk factors that may trigger Parkinsonian features in people with COVID may additionally be elucidated, where the virus may act as a trigger to such symptoms. This interview took place at the 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
